Inactivated Japanese encephalitis virus vaccination imprints fusion loop-biased antibody responses that are attenuated by repeated live-attenuated dengue vaccination

Prior inactivated Japanese encephalitis virus (JEV) vaccination imprints a fusion loop-biased, low-potency antibody response with enhanced antibody-dependent enhancement risk, which can be mitigated by a complete series of live-attenuated dengue vaccination that redirects immunity toward non-fusion-loop epitopes.

The Gist

The Big Picture: The "Muscle Memory" of Your Immune System

Imagine your immune system is a highly trained security team. When it sees a bad guy (a virus) for the first time, it takes a photo, memorizes the face, and creates a "Wanted" poster. If that same bad guy shows up again, the team recognizes him instantly and attacks.

This paper is about what happens when your security team has already memorized one type of bad guy, and then you try to train them on a related but different bad guy. Specifically, it looks at the relationship between the Japanese Encephalitis (JE) virus and the Dengue virus. They are distant cousins in the "Flavivirus" family—they look very similar, but they aren't the same.

The Experiment: Three Groups of Trainees

The researchers took a group of healthy adults who had never seen these viruses before and split them into three teams to test how different vaccination schedules affected their immune memory:

1. The Fresh Start Team (JEV-Naïve): These people only got the Dengue vaccine. They had no prior training against the JE virus.
2. The Double-Dose Team (Simultaneous): These people got the JE vaccine and the Dengue vaccine at the exact same time.
3. The Sequenced Team (JEV-Primed): These people got the JE vaccine first. Six months later, they got the Dengue vaccine.

The Discovery: The "Fusion Loop" Trap

When the Dengue vaccine was introduced, the researchers looked closely at the antibodies (the security guards) the body produced. They found a fascinating pattern:

The "Old Habit" Problem:
For the Sequenced Team (those who got the JE vaccine first), their immune system got stuck in a rut. Because the JE and Dengue viruses look so similar in one specific spot (called the Fusion Loop), the immune system kept pulling out its old "JE photos" to fight the Dengue virus.

• The Analogy: Imagine a security guard who memorized a robber wearing a red hat. Then, a new robber shows up wearing a red hat but a blue coat. The guard ignores the blue coat and focuses entirely on the red hat.
• The Result: The Sequenced Team produced antibodies that were very good at recognizing that shared "red hat" (the Fusion Loop), but they were bad at recognizing the unique parts of the Dengue virus (the blue coat).

The Consequences of this "Red Hat" Focus:

1. Broad but Weak: These antibodies could recognize many different viruses (Dengue, Zika, JE) because they all wear the "red hat." However, they weren't very good at actually stopping the virus. They were like a security guard who recognizes the face but can't stop the thief from running away.
2. The Danger Zone (ADE): This is the scary part. Because these antibodies were so focused on the shared "red hat," they sometimes actually helped the Dengue virus get into cells instead of killing it. This is called Antibody-Dependent Enhancement (ADE). It's like the security guard accidentally opening the door for the thief because they thought the thief was a friend from the old neighborhood.

The Plot Twist: The "Full Course" Saves the Day

The researchers then looked at what happened when the Sequenced Team finished the full three-dose series of the Dengue vaccine (instead of just the first dose).

The "New Training" Effect:
After receiving all three doses, the immune system finally woke up and realized, "Hey, this new virus is different! We need to learn the new details!"

• The Analogy: After weeks of training, the security guard finally looks at the blue coat. They stop obsessing over the red hat and start memorizing the unique features of the new robber.
• The Result: The "red hat" focus faded away. The immune system started making antibodies that targeted the unique parts of the Dengue virus. These new antibodies were much better at neutralizing the virus and much less likely to accidentally help it infect cells.

The Takeaway: Timing and Dose Matter

This paper teaches us three important lessons about vaccines:

1. History Matters: If you have been vaccinated against one virus (like JE), it can "imprint" your immune system. When you get a related vaccine (like Dengue) later, your body might default to the old memory instead of learning the new details.
2. The "Red Hat" is Risky: Antibodies that only target shared, common parts of viruses are often weak and can sometimes make infections worse (via ADE).
3. Don't Give Up: Even if your immune system gets stuck in the "old habit," a full course of the new vaccine (multiple doses) can break that habit. It forces the body to learn the new, unique details, creating a stronger and safer defense.

In short: Your immune system has a habit of relying on old memories. If you've had a JE vaccine, your body might initially try to fight Dengue with an "old map." But if you complete the full Dengue vaccine schedule, your body learns to draw a "new map" that actually works.

Technical Summary

1. Problem Statement

The study addresses the complex immunological phenomenon of immune imprinting (or original antigenic sin) in the context of sequential flavivirus vaccinations. Specifically, it investigates how prior exposure to the inactivated Japanese encephalitis virus (JEV) vaccine (IXIARO) influences the humoral immune response to the live-attenuated tetravalent dengue vaccine (CYD-TDV, Dengvaxia).

• Context: In regions where JEV and Dengue co-circulate, individuals often receive both vaccines. Previous studies suggest that JEV vaccination may increase the risk of symptomatic dengue or severe illness upon subsequent infection.
• Knowledge Gap: While it is known that flaviviruses share structural similarities, the specific epitope targeting (e.g., fusion loop vs. type-specific domains) and functional consequences (neutralization vs. antibody-dependent enhancement) of sequential JEV and Dengue vaccination in humans were not fully characterized.
• Hypothesis: Prior inactivated JEV vaccination primes memory B cells that, upon subsequent Dengue vaccination, preferentially recall antibodies targeting the conserved fusion loop epitope (FLE) of the Dengue envelope (E) protein. This FLE-biased response is hypothesized to result in broad but low-potency neutralization and increased antibody-dependent enhancement (ADE).

2. Methodology

The study utilized longitudinal serum samples from a Phase II, randomized, open-label clinical trial (NCT01943825) involving 45 healthy, flavivirus-naïve adults (aged 18–45).

• Study Groups: Participants were categorized into three groups based on vaccination history:
  1. JEV-Naïve (DV-CYD): Received only the accelerated CYD-TDV schedule (0, 2, 6 months).
  2. Simultaneous (JE-IXIARO+DV-CYD): Received the first dose of CYD-TDV and IXIARO simultaneously.
  3. Sequential Priming (JE-IXIARO→DV-CYD): Received IXIARO 6 months prior to the CYD-TDV series.
• Sampling: Serum was collected at baseline (Day 0) and longitudinally at Days 28, 84, 196, and 336 post-Dengue vaccination.
• Assays Performed:
  • Binding Assays: Multiplex MSD (Meso Scale Discovery) assays to measure IgG/IgM binding to DENV1-4 VLPs, JEV VLPs, and YFV NS1.
  • Epitope Specificity (BOB): Blockade-of-binding assays using monoclonal antibodies 4G2 (FLE-specific) and 4E11 (EDIII-specific) to quantify the proportion of antibodies targeting the fusion loop vs. domain III.
  • Structural Epitope Mapping: Binding assays using recombinant DENV-2 E-dimers (Wild-Type vs. FLE-mutant G106D). The mutant disrupts FLE accessibility while preserving the dimer structure, allowing calculation of "FLE dominance" (percentage loss of binding to mutant vs. WT).
  • Neutralization: Plaque Reduction Neutralization Tests (PRNT50) for DENV1-4 and reporter virus particle (RVP) neutralization for Zika virus (ZIKV).
  • Functional Assays: In vitro Antibody-Dependent Enhancement (ADE) assays using FcγRIIa-expressing K562 cells and DENV-2 RVPs to measure Peak Enhancement Titer (PET) and Area Under the Curve (AUC).
  • Statistical Analysis: Non-parametric tests (Kruskal-Wallis), correlation analyses (Spearman), and multivariable linear regression to identify predictors of ADE.

3. Key Contributions

• Mechanistic Insight into Imprinting: The study provides direct evidence that inactivated JEV vaccination imprints the immune system to preferentially recall FLE-specific memory B cells upon Dengue vaccination, rather than generating a balanced response.
• Differentiation of Vaccine Platforms: It demonstrates that the timing and platform (inactivated vs. live-attenuated) are critical determinants of epitope dominance. Simultaneous administration partially mitigates this bias, while sequential priming strongly enforces it.
• Structural Validation: The use of the FLE-mutant E-dimer (G106D) allowed for the direct quantification of FLE-dependent antibodies in native protein structures, moving beyond peptide-based assays.
• Functional Correlation: The research links specific epitope bias (FLE) directly to functional outcomes: broad cross-neutralization but increased FcγRIIa-mediated ADE, independent of neutralization potency.
• Reversibility: It shows that a full three-dose series of live-attenuated Dengue vaccine can eventually overcome the initial FLE imprinting, recruiting new B cells targeting non-FLE epitopes (like EDIII).

4. Key Results

A. Immune Imprinting and Epitope Bias

• FLE Dominance: Individuals primed with IXIARO (Sequential group) exhibited significantly higher levels of 4G2 FLE-like antibodies at Day 28 compared to JEV-naïve or simultaneous groups.
• Structural Confirmation: Sera from the Sequential group showed a marked reduction in binding to the FLE-mutant E-dimer compared to Wild-Type, confirming that a large fraction of their antibodies were strictly FLE-dependent. In contrast, the Simultaneous group showed less FLE dominance and more binding to the mutant, indicating recruitment of non-FLE antibodies.
• EDIII Response: The Sequential group had delayed and lower responses to EDIII (4E11-like) antibodies initially, which only caught up after the full 3-dose series.

B. Neutralization Breadth vs. Potency

• Broad but Weak: The FLE-biased response in the Sequential group resulted in broader neutralization (neutralizing more DENV serotypes and ZIKV) but lower potency (lower PRNT50 titers) compared to groups with more type-specific responses.
• Correlation: There was a positive correlation between 4G2 FLE-like antibody levels and the breadth of neutralization (number of flaviviruses neutralized), but not necessarily the strength of neutralization.

C. Antibody-Dependent Enhancement (ADE)

• Increased ADE: The Sequential group (JEV-primed) demonstrated significantly higher FcγRIIa-mediated ADE activity (higher PET and AUC) at Day 28 compared to other groups.
• Predictive Modeling: Multivariable regression analysis identified 4G2 FLE-like antibody levels and FLE dominance as the primary independent predictors of ADE activity. Neutralization titers did not predict ADE, suggesting that epitope specificity, not just antibody quantity, drives enhancement.
• Mitigation: Following the completion of the full 3-dose CYD-TDV series (Days 196 and 336), the Sequential group showed a reduction in FLE dominance and a corresponding decrease in ADE activity, approaching levels seen in JEV-naïve individuals.

5. Significance

• Vaccine Strategy Implications: The findings suggest that the sequence of flavivirus vaccination matters. Prior inactivated JEV vaccination may skew the subsequent Dengue immune response toward a "dangerous" profile (high ADE, low neutralization potency) in the short term.
• Overcoming Imprinting: The study offers a potential solution: a full, multi-dose live-attenuated regimen can overcome the initial FLE imprinting by providing sufficient antigenic stimulation to recruit naive B cells targeting protective, type-specific epitopes (EDIII/EDE).
• Clinical Relevance: This helps explain epidemiological observations where JEV-vaccinated individuals may experience more severe dengue outcomes. It underscores the need to consider immune history when deploying Dengue vaccines in endemic areas with prior JEV vaccination programs.
• Future Directions: The authors highlight the need for longitudinal studies linking these epitope-specific functional markers to actual clinical disease outcomes and further research into the clonal composition of these B cell responses.

In summary, the paper establishes that inactivated JEV vaccination creates a specific immune imprint favoring conserved fusion loop epitopes, which initially compromises the quality of the Dengue vaccine response by promoting ADE. However, this imprint is not permanent and can be modulated by the intensity and duration of subsequent live-attenuated antigen exposure.